Quantative HBsAg level correlates dendritic cells maturation in chronic hepatitis B patients - 20/06/20
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 8 |
| Iconographies | 5 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Frequencies of myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) were lower in CHB patients. |
• | pDCs frequencies and mDCs maturation markers expression were increased after entecavir (ETV) treatment. |
• | Patients with higher baseline HBsAg levels showed a poorer maturation status than those with low baseline HBsAg levels, regardless of changes in HBsAg levels after treatment. |
Summary |
Background |
In order to better understand the role of Dendritic cells (DCs) in Chronic Hepatitis B (CHB), we investigated the frequencies and maturation markers on DCs in CHB patients and its change during entecavir treatment.
Methods |
Twenty-six CHB patients on anti-virus treatment for 48 weeks were included in this study. Patients’ blood samples were collected on every 3 months since starting treatment. Samples on baseline and after 48 weeks treatment were examined using flow-cytometry to investigate frequencies and maturation markers of DCs.
Results |
The frequencies of myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) were lower in CHB patients than healthy controls on baseline. pDCs frequencies and mDCs maturation markers expression were increased after entecavir (ETV) treatment. Patients with higher baseline HBsAg levels showed a poorer maturation status than those with low baseline HBsAg levels, regardless of changes in HBsAg levels after treatment.
Conclusions |
Entecavir treatment could restore the decreased DCs frequencies in CHB patients and improve DCs maturation levels. Baseline HBsAg level is an important factor that affecting DCs.
Le texte complet de cet article est disponible en PDF.Keywords : Chronic Hepatitis B, Dendritic Cells, HBsAg
Plan
Vol 44 - N° 3
P. 321-328 - juin 2020 Retour au numéro
Article précédent
- C1GALT1C1/COSMC is a novel prognostic biomarker for hepatocellular carcinoma
- Bo Shen, Yifan Tong, Zheyong Li, Han Yan, Fang Ye, Yifan Wang, Xiujun XCai
- Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil
- Bruna Forte Aguiar, Guilherme Rodrigues Fernandes Campos, João Paulo Vilela Rodrigues, Nayara Nathie Marques, Bárbara Floriano Molina, Cintia Bittar, Fernanda Fernandes Souza, Ana de Lourdes Candolo Martinelli, Paula Rahal, Leonardo Régis Leira Pereira
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?